US Patent Office Plans Review In Boston-Edwards TAVR Battle
Executive Summary
The US Patent & Trademark Office has found three grounds on which to review four claims in a Boston Scientific TAVR patent being challenged by Edwards Lifesciences. The companies have seen mixed recent verdicts in European bodies on related patent disputes.
You may also be interested in...
Boston Sci Wins Latest TAVR Patent Dispute Against Edwards
The European Patent Office sided with Boston Scientific on April 16 in agreeing to revoke an Edwards Lifesciences patent on a technology used in transcatheter aortic valve replacement (TAVR) devices.
Edwards Letting German Centers Stock-Up On Sapien 3 Ahead Of Patent Ruling
As its dispute with Boston Scientific over transcatheter aortic valve replacement technology patents rumbles on, Edwards Lifesciences is offering German interventionalists the option to buy six-months' worth of its Sapien 3 inventory in anticipation of a potential disruption to the supply flow.
Medtronic Will Pay Edwards More Than $1 Billion To Settle TAVR Dispute
A settlement between the two companies dismissing all pending patent litigation related to transcatheter valve replacement technologies ends years of legal wrangling and ensures that the U.S. TAVR market will have at least two competitors.